Abstract | PURPOSE: METHODS: RESULTS: Forty-nine patients were enrolled in the study. Stage II was present in 16 patients (32.7%) and stage III in 33 patients (67.3%). Relevant toxicities were nausea/ vomiting grades III-IV in 6 patients (12.2%) and neutropenia grade III-IV in 33 patients (67.3%). The overall clinical response rate was 83.7%. Partial response was observed in 25 patients (51%), complete response in 16 patients (32.7%), stable disease in 7 patients (14.3%) and progression in 1 patient. Thirty-three non- inflammatory breast cancer patients underwent surgery, 29 with breast-conserving surgery (87.9%). Pathological complete response was found in 5 patients (15.1%). CONCLUSIONS:
|
Authors | David Aguiar Bujanda, Uriel Bohn Sarmiento, Miguel Angel Cabrera Suárez, Marta Pavcovich Ruiz, Miguel Angel Limeres González, José Aguiar Morales |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 132
Issue 5
Pg. 332-8
(May 2006)
ISSN: 0171-5216 [Print] Germany |
PMID | 16435143
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Epirubicin
- Cyclophosphamide
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, pathology, surgery)
- Carcinoma
(drug therapy, pathology, surgery)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Epirubicin
(administration & dosage, adverse effects)
- Female
- Humans
- Infusions, Intravenous
- Mastectomy, Segmental
- Middle Aged
- Neoadjuvant Therapy
- Paclitaxel
(administration & dosage, adverse effects)
- Treatment Outcome
|